<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339468</url>
  </required_header>
  <id_info>
    <org_study_id>MR-08-04-KOR_Main</org_study_id>
    <nct_id>NCT01339468</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation</brief_title>
  <acronym>MAIN</acronym>
  <official_title>A Phase IV, Randomized, Open-label, Comparative, Single-center Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf® (Modified Release Tacrolimus) and Prograf® (Tacrolimus) in de Novo Living Donor Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and compare the pharmacokinetic parameters of
      tacrolimus from Advagraf and Prograf in de nove living donor liver transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2011</start_date>
  <completion_date type="Actual">May 27, 2014</completion_date>
  <primary_completion_date type="Actual">May 27, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24 (Area under the curve for 24 hours) of tacrolimus plasma concentration</measure>
    <time_frame>Day 6 and day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum concentration) of tacrolimus plasma concentration</measure>
    <time_frame>Day 6 and day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the composite event: graft loss (defined as re-transplantation or death) or biopsy confirmed acute rejection (BCAR)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first incidence of the composite event: graft loss (defined as re-transplantation or death) or biopsy confirmed acute rejection (BCAR)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events and lab-tests</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Prograf therapy followed by oral Advagraf therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Prograf therapy followed by oral Prograf therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>FK506E</other_name>
    <other_name>modified release tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>tacrolimus</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject receiving a primary, partial liver graft from a living donor

          -  subject must receive the first dose of tacrolimus and corticosteroids after operation
             and are expected to be maintained on tacrolimus throughout the study. MMF could be
             combined

        Exclusion Criteria:

          -  subjects receiving a multi-organ transplant or having previously received an organ
             transplant (including liver re-transplantation)

          -  subjects receiving an auxiliary graft or in whom a bio-artificial liver (cell system)
             has been used

          -  subjects allergic or intolerant to macrolide antibiotics or tacrolimus

          -  subjects requiring immunosuppressive treatment and / or systemic chemotherapy prior to
             transplantation

          -  subjects with malignancies or a history of malignancy within the last 5 years, with
             the exception of those with basalioma or squamous cell carcinoma of the skin

          -  subjects with systemic infection requiring treatment, except viral hepatitis

          -  subjects with severe diarrhoea, vomiting, active peptic ulcer or gastrointestinal
             disorder that may affect the absorption of tacrolimus

          -  subjects with serum creatinine &gt; 1.5mg/dl

          -  subjects taking or having taken potassium preserved diuretics

          -  subjects with any form of substance abuse, psychiatric disorder or condition which, in
             the opinion of the investigator, may complicate communication with the investigator

          -  subjects participating or having participated in another clinical trial and/or those
             taking or having taken an investigational / non-registered drug in the past 28 days

          -  subjects or donors known to be HIV positive

          -  donors known to be HBV, HCV positive and/or IgM positive of CMV, EBV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=131</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=130</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advagraf</keyword>
  <keyword>prograf</keyword>
  <keyword>living donor liver transplantation</keyword>
  <keyword>FK506</keyword>
  <keyword>Immunosuppressant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

